Figure 2.
hiPSC-CMs assay can replicate the HCV-NS5B NI/Amiodarone cardiac DDIs observed in clinic and preclinical models, provide a competitive advantage for early screening/de-risking of new HCV-NI candidates, and rapidly assess the putative mechanism(s) responsible of DDIs.